Mineralys Therapeutics, Inc. (MLYS) Stock Ticker
MLYS right now
Market factors today
Unlock the full MLYS picture
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
MLYS stock facts
| Ticker symbol | MLYS |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $2.3B |
| CEO | Jon Congleton |
| Employees | 76 |
| Headquarters | Radnor, PA, US |
| IPO date | 2023-02-10 |
| Website | mineralystx.com |
What you can see for MLYS on Tickr
Live MLYS price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the MLYS report.
Rankings
FAQ
What is the ticker symbol for Mineralys Therapeutics, Inc.?
The ticker symbol for Mineralys Therapeutics, Inc. is MLYS, listed on the NASDAQ Global Select.
What is MLYS?
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected…